Variables | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
Age | ||||||
< 50 | 1 | 1 | ||||
≥ 50 | 0.577 | 0.278–1.197 | 0.140 | 0.666 | 0.307–1.445 | 0.304 |
DM | ||||||
No | 1 | |||||
Yes | 0.710 | 0.154–3.269 | 0.710 | |||
HTN | ||||||
No | 1 | 1 | ||||
Yes | 0.413 | 0.120–1.429 | 0.163 | 0.426 | 0.116–1.566 | 0.199 |
Diagnosis, year | ||||||
2007–2013 | 1 | 1 | ||||
2014–2020 | 1.624 | 0.697–3.781 | 0.261 | 0.885 | 0.317–2.469 | 0.815 |
Histology | ||||||
Non-SCC | 1 | |||||
SCC | 1.050 | 0.492–2.239 | 0.899 | |||
FIGO stage | ||||||
I-II | 1 | |||||
III-IV | 0.947 | 0.463–1.935 | 0.881 | |||
IMRT | ||||||
No | 1 | 1 | ||||
Yes | 1.513 | 0.737–3.108 | 0.259 | 1.136 | 0.498–2.592 | 0.761 |
RT | ||||||
Primary | 1 | |||||
After 1st recur | 0.974 | 0.347–2.733 | 0.960 | |||
Bevacizumab administration | ||||||
No | 1 | 1 | ||||
Yes | 3.026 | 1.199–7.640 | 0.019 | 3.273 | 1.177–9.096 | 0.023 |